Perfuze published a three-arm benchtop comparison of its Millipede88 aspiration catheter in Clinical Neuroradiology. First-pass success in middle cerebral artery models came in at 88 percent for the 0.088-inch Millipede88, 71 percent for conventional aspiration through a 0.071-inch catheter and 62 percent for cyclic aspiration through the same size. Complete clot ingestion ran 82 percent, 59 percent and 62 percent.
Each arm ran 34 ovine clot analogs covering soft, mixed and stiff clots, through silicone models of the iliofemoral vessels, aortic arch and Circle of Willis with blood-mimicking fluid. After up to three passes, final revascularization reached 91 percent in both middle cerebral artery and internal carotid models, against roughly 80 percent for the other two techniques. Ameer Hassan led the study.
Bench work is not clinical evidence and a reviewer will read it that way, but it is the comparison a 510(k) leans on when the predicate is a smaller catheter. Perfuze cleared Millipede88 in March as the first standalone 0.088-inch catheter for direct aspiration. The Galway company enrolled more than 180 patients in 2025 and is running a limited US release at comprehensive stroke centers.